?ou'd think that if TIS had any interest in raising their share price that they would comment on the after care of the original trial patients. I realise that that may not be official reporting, but I'm sure there are a lot like me who want to know about "Then what happened". Its easy for them to find out. Pretty difficult for shareholders. Maybe easy for big pharmas ? Yes I've been nibbling, too. I'd go harder if I knew wot append next. Japes
TIS Price at posting:
44.4¢ Sentiment: LT Buy Disclosure: Held